COPENHAGEN, Denmark, Dec. 6, 2011 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that Genentech and Biogen Idec have appealed the judgment in favor of GlaxoSmithKline (GSK) in a patent infringement case involving Arzerra brought against GSK by Genentech and Biogen Idec.